PLGA Based Nanoparticles for Targeted Drug Delivery – A Review

Many scientists developed poly (lactic co-glycolic acid) (PLGA) nanoparticles, which are recognized as an enabling technology in the field of nanomedicine. This article reviews the current advancements in the design, characterization, and use of PLGA nanoparticles as a drug-delivery tool. It highlights the shift from batch fabrication to microfluidics for the preparation of nanoparticles, since it enhances the dimensional size and monodispersity of nanoparticles. This article also highlights crucial advancements in interfacial science, i.e., Stealth PEGylation, mucus-penetrating, and platelet membrane cloak technologies. Moreover, it explores the range of different applications, including the use of nanoparticles to convey highCRISPRCas9 plasmids, anti-cancer therapeutic applications to induce necroptosis, anti-chronic inflammatory respiratory disease, and many other usages. It mentions some issues, such as the phenomenon of the protein corona, the need to use standardized in vitro models, and the necessity to develop new standardized in vitro models, yet it concludes that PLGA nanoparticles are still an enabling design technology, since, through "design-by-intent" methodology, it can accommodate the need to develop novel targeted therapies.